HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that, following recent communications with the U.S. Food and Drug Administration (FDA), the Company is commencing its Phase 3 development program for NX-1207, Nymox’s investigational product for the treatment of benign prostatic hyperplasia (BPH). The Company will begin Phase 3 clinical trials in the U.S. later this year to support a New Drug Application (NDA) to the FDA. Further information about the Phase 3 program will be provided prior to the initiation of the clinical trials.
